|
1
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fuller GN and Scheithauer BW: The 2007
revised World Health Organization (WHO) classification of tumours
of the central nervous system: Newly codified entities. Brain
Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Talacchi A, Turazzi S, Locatelli F, Sala
F, Beltramello A, Alessandrini F, Manganotti P, Lanteri P, Gambin
R, Ganau M, et al: Surgical treatment of high-grade gliomas in
motor areas. The impact of different supportive technologies: A
171-patient series. J Neurooncol. 100:417–426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nitta M, Muragaki Y, Maruyama T, Iseki H,
Ikuta S, Konishi Y, Saito T, Tamura M, Chemov M, Watanabe A, et al:
Updated therapeutic strategy for adult low-grade glioma stratified
by resection and tumor subtype. Neurol Med Chir (Tokyo).
53:447–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martinho O, Granja S, Jaraquemada T,
Caeiro C, Miranda-Gonçalves V, Honavar M, Costa P, Damasceno M,
Rosner MR, Lopes JM and Reid RM: Downregulation of RKIP is
associated with poor outcome and malignant progression in gliomas.
PLoS One. 7:e307692012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joazeiro CA and Weissman AM: RING finger
proteins: Mediators of ubiquitin ligase activity. Cell.
102:549–552. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen Z, Jiang X, Zeng C, Zheng S, Luo B,
Zeng Y, Ding R, Jiang H, He Q, Guo J and Jie W: High expression of
ubiquitin-conjugating enzyme 2C (UBE2C) correlates with
nasopharyngeal carcinoma progression. BMC Cancer. 13:1922013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rape M and Kirschner MW: Autonomous
regulation of the anaphase-promoting complex couples mitosis to
S-phase entry. Nature. 432:588–595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rape M, Reddy SK and Kirschner MW: The
processivity of multiubiquitination by the APC determines the order
of substrate degradation. Cell. 124:89–103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Parris TZ, Danielsson A, Nemes S, Kovács
A, Delle U, Fallenius G, Möllerström E, Karlsson P and Helou K:
Clinical implications of gene dosage and gene expression patterns
in diploid breast carcinoma. Clin Cancer Res. 16:3860–3874. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin J, Raoof DA, Wang Z, Lin MY, Thomas
DG, Greenson JK, Giordano TJ, Orringer MB, Chang AC, Beer DG and
Lin L: Expression and effect of inhibition of the
ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
Neoplasia. 8:1062–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R,
Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari LH, et al:
Bortezomib stabilizes mitotic cyclins and prevents cell cycle
progression via inhibition of UBE2C in colorectal carcinoma. Am J
Pathol. 178:2109–2120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wagner KW, Sapinoso LM, El-Rifai W,
Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL and Hampton
GM: Overexpression, genomic amplification and therapeutic potential
of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of
diverse anatomic origin. Oncogene. 23:6621–6629. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ieta K, Ojima E, Tanaka F, Nakamura Y,
Haraguchi N, Mimori K, Inoue H, Kuwano H and Mori M: Identification
of overexpressed genes in hepatocellular carcinoma, with special
reference to ubiquitin-conjugating enzyme E2C gene expression. Int
J Cancer. 121:33–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berlingieri MT, Pallante P, Guida M, Nappi
C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A,
Barbareschi M, et al: UbcH10 expression may be a useful tool in the
prognosis of ovarian carcinomas. Oncogene. 26:2136–2140. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donato G, Iofrida G, Lavano A, Volpentesta
G, Signorelli F, Pallante PL, Berlingieri MT, Pierantoni MG,
Palmieri D, Conforti F, et al: Analysis of UbcH10 expression
represents a useful tool for the diagnosis and therapy of
astrocytic tumors. Clin Neuropathol. 27:219–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang L, Huang CG, Lu YC, Luo C, Hu GH,
Liu HM, Chen JX and Han HX: Expression of ubiquitin-conjugating
enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 1201:161–166.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang W, Qiu XG, Chen BS, Li SW, Cui Y,
Ren H and Jiang T: Antiangiogenic therapy with bevacizumab in
recurrent malignant gliomas: Analysis of the response and core
pathway aberrations. Chin Med J (Engl). 122:1250–1254.
2009.PubMed/NCBI
|
|
20
|
Jiang L, Wang T, Bao Y, Qian J, Wu XJ, Hu
GH and Lu YC: A study of UbcH10 expression and its association with
recurrence of meningiomas. J Surg Oncol. 106:327–331. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Townsley FM, Aristarkhov A, Beck S,
Hershko A and Ruderman JV: Dominant-negative cyclin-selective
ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase.
Proc Natl Acad Sci USA. 94:2362–2367. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamanaka A, Hatakeyama S, Kominami K,
Kitagawa M, Matsumoto M and Nakayama K: Cell cycle-dependent
expression of mammalian E2-C regulated by the anaphase-promoting
complex/cyclosome. Mol Biol Cell. 11:2821–2831. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujita T, Ikeda H, Taira N, Hatoh S, Naito
M and Doihara H: Overexpression of UbcH10 alternates the cell cycle
profile and accelerate the tumor proliferation in colon cancer. BMC
Cancer. 9:872009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M,
Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2
ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173.
2003.PubMed/NCBI
|
|
25
|
Troncone G, Guerriero E, Pallante P,
Berlingieri MT, Ferraro A, Del Vecchio L, Gorrese M, Mariotti E,
Iaccarino A, Palmieri EA, et al: UbcH10 expression in human
lymphomas. Histopathology. 54:731–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Ree JH, Jeganathan KB, Malureanu L and
van Deursen JM: Overexpression of the E2 ubiquitin-conjugating
enzyme UbcH10 causes chromosome missegregation and tumor formation.
J Cell Biol. 188:83–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumoto A, Ishibashi Y, Urashima M,
Omura N, Nakada K, Nishikawa K, Shida A, Takada K, Kashiwagi H and
Yanaga K: High UBCH10 protein expression as a marker of poor
prognosis in esophageal squamous cell carcinoma. Anticancer Res.
34:955–961. 2014.PubMed/NCBI
|
|
28
|
Li SZ, Song Y, Zhang HH, Jin BX, Liu Y,
Liu WB, Zhang XD and Du RL: UbcH10 overexpression increases
carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
Sci Rep. 4:69102014. View Article : Google Scholar : PubMed/NCBI
|
